🇪🇺 Erenumab Dose 1 in European Union

EMA authorised Erenumab Dose 1 on 26 July 2018

Marketing authorisation

EMA — authorised 26 July 2018

  • Application: EMEA/H/C/004447
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Aimovig
  • Indication: Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.
  • Status: approved

Read official source →

Other Neurology approved in European Union

Frequently asked questions

Is Erenumab Dose 1 approved in European Union?

Yes. EMA authorised it on 26 July 2018.

Who is the marketing authorisation holder for Erenumab Dose 1 in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.